AVROBIO’s mission is to free people from a lifetime of genetic disease with a single dose of gene therapy. They aim to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Their clinical-stage programs include Fabry disease, Gaucher disease and cystinosis and they also are advancing a program in Pompe disease. AVROBIO is powered by the plato™ gene therapy platform, a foundation designed to scale gene therapy worldwide.

Headquarters Cambridge, MA with an office in Toronto, ON
Website www.avrobio.com
Pipeline Phase 2
Partners Center for Commercialization of Regenerative Medicine (CCRM)
Twitter @avrobio